Researchers designed a PCR-based test for pyrethroid resistance based on a cytochrome P450 allele that is common in Anopheles funestus mosquitoes from Malawi.
The company had been warned in March that it failed to meet a listing requirement calling for a minimum $1 per share closing price of its common stock.
Clinicians are using Roche's Cobas Omni Utility Channel to run lab-developed PCR tests alongside in vitro diagnostic kits, freeing valuable resources for labs.
The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
